Follow the progress of Hemolens Diagnostics
This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Follow the progress of Hemolens Diagnostics
November 21, 2022
On 10 November at the ISPOR 2022 Europe conference, independent research company Panaxea presented the results of a study evaluating the functionality of FFR-CT versus standard diagnostics in patients with stable (continuous) chest pain in the Netherlands.
A virtual fractional flow reserve (FFR-CT) assessment developed from coronary computed tomography angiography (CCTA) could provide a non-invasive alternative to current diagnostics.
Panaxea study for Hemolens Diagnostics was aimed at was set up to assess the healthcare costs and effects of FFR-CT guided diagnostics compared to standard diagnostics for patients with stable chest pain in The Netherlands over a time period of one year. Please keep in mind that this is an early HTA (HTA – Health Technology Assessment) study, meaning that not everything is based on the best available data.
A decision tree model was developed to assess cost differences from a hospital perspective, as well as the probability of making correct diagnoses and the risk of adverse cardiovascular events. It can be noted that FFR-CT scored better in all three parameters assessed than current diagnostics over a one-year period in the Netherlands.If you look at the table you can see that the FFR-CT scored better on all three mentioned factors than the standard care within one year in The Netherlands.
In addition to this analysis, one-way sensitivity analyses were conducted to determine the main drivers of the cost difference between the strategies. It can be noted that the main drivers of the difference in costs were the probabilities and costs of revascularization and test characteristics of FFR-CT and CCTA.
At last, a threshold analysis showed that the added price of the FFR-CT analysis should be below €793 per patient to be the least costly option in this model.
To conclude, our early HTA findings suggest that FFR-CT may reduce total healthcare spending, probability of incorrect diagnosis, and risk of major adverse cardiovascular events compared to current diagnostics for patients with stable chest pain in The Netherlands. Future cost-effectiveness studies could determine value-based pricing for FFR-CT, quantify the economic value of the anticipated therapeutic impact, and decrease some of the uncertain parameters used in the early HTA study.
June 23, 2023
Warsaw, 22 June 2023. – Wrocław-based Hemolens Diagnostics has been awarded this year’s “Polonica Progressio” award by the Minister...
June 21, 2023
Physical activity plays a key role in the prevention of cardiovascular disease and other cardiovascular disorders. Research shows that...
May 26, 2023
Wrocław, April 21, 2023. – Wrocław-based Hemolens Diagnostics has been recognized in this year’s Polish Product of the Future...
March 20, 2023
Huawei Startup Academy is an initiative that was created for young, promising startups, offering them not only the opportunity...
March 7, 2023
The Start-Up-Med competition is a prestigious initiative organized by PTWP Group (Polish Association for Entrepreneurship Support), publisher of, among...
March 1, 2023
Rebranding is a process aimed at changing one or more elements of a brand’s image communication. This includes changes...
February 24, 2023
The research project ‘HEMOFLOW cloud platform for non-invasive hemodynamic diagnostics’, No. POIR.01.01.01-00-0393/19, aims to assess the diagnostic value of...
January 11, 2023
What is FFR Measuring fractional flow reserve (FFR) is currently the ‘gold standard’ in the diagnostic assessment of coronary...
Cardiolens FFR-CT Pro is a coronary physiologic simulation software for the clinical quantitative and qualitative analysis of previously acquired Coronary Computed Tomography Angiography (CCTA) and optionally with Continuous Non-invasive Blood Pressure (CNBP) data for assessment of patients with suspected Chronic Coronary Syndromes (CCS). It provides hemodynamic diagnostic factor FFR-CT (Fractional Flow Reserve with Computed Tomography), a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images and optionally from CNBP measurement. The factor FFR-CT at the output of Cardiolens FFR-CT Pro device is intended to support the functional evaluation of coronary artery disease. The Cardiolens FFR-CT Pro outputs are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of Cardiolens FFR-CT Pro are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.